| Title: |
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes |
| Authors: |
Facon, T; Moreau, P; Weisel, K; Goldschmidt, H; Usmani, SZ; Chari, A; Plesner, T; Orlowski, RZ; Bahlis, N; Basu, S; Hulin, C; Quach, H; O’Dwyer, M; Perrot, A; Jacquet, C; Venner, CP; Raje, N; Tiab, M; Macro, M; Frenzel, L; Leleu, X; Cook, G; Wang, G; Pei, H; Krevvata, M; Carson, R; Borgsten, F; Kumar, SK |
| Publisher Information: |
Springer Nature |
| Publication Year: |
2025 |
| Collection: |
The University of Melbourne: Digital Repository |
| Description: |
In the MAIA study, daratumumab plus lenalidomide and dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). We report updated efficacy and safety from MAIA (median follow-up, 64.5 months), including a subgroup analysis by patient age ( |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| ISSN: |
0887-6924 |
| Relation: |
https://hdl.handle.net/11343/360018 |
| Availability: |
https://hdl.handle.net/11343/360018 |
| Rights: |
https://creativecommons.org/licenses/by/4.0 ; CC BY |
| Accession Number: |
edsbas.3DBC983F |
| Database: |
BASE |